Page last updated: 2024-12-08

orotidylic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

orotidylic acid: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

orotidine 5'-phosphate : A pyrimidine ribonucleoside 5'-monophosphate having 6-carboxyuracil as the nucleobase. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID160617
CHEMBL ID1207358
CHEBI ID15842
SCHEMBL ID21891
MeSH IDM0046951

Synonyms (54)

Synonym
6-carboxy-5'-uridylic acid
2,6-dioxo-3-(5-o-phosphono-beta-d-ribofuranosyl)-1,2,3,6-tetrahydropyrimidine-4-carboxylic acid
orotidine 5'-(dihydrogen phosphate)
CHEBI:15842 ,
4-pyrimidinecarboxylic acid, 1,2,3,6-tetrahydro-2,6-dioxo-3-(5-o-phosphono-beta-d-ribofuranosyl)- (9ci)
omp (nucleotide)
ometoprim
orotidine-5'-phosphate
5'-omp
OMP ,
1-[3,4-dihydroxy-5-(phosphonooxymethyl)tetrahydrofuran-2-yl]-2, 4-dioxo-1h-pyrimidine-6-carboxylic acid
orotidine monophosphate
orotidine, 5'-phosphate (6ci,7ci)
4-pyrimidinecarboxylic acid, 1,2,3,6-tetrahydro-2,6-dioxo-3-(5-o-phosphono-beta-d-ribofuranosyl)-
orotidine 5'-monophosphate
orotidine, 5'-(dihydrogen phosphate) (8ci)
orotidine-5'-monophosphate
5-(dihydrogen phosphate)orotidine
uridine, 6-carboxy-, 5'-(dihydrogen phosphate)
3-[(2r,3r,4s,5r)-3,4-dihydroxy-5-[(phosphonooxy)methyl]oxolan-2-yl]-2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylic acid
orotidine 5-monophosphate
bdbm21336
orotidine 5'-phosphate
orotidylic acid
2149-82-8
C01103
DB02957
3-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(phosphonooxymethyl)oxolan-2-yl]-2,6-dioxopyrimidine-4-carboxylic acid
CHEMBL1207358
h0arn8u4y9 ,
unii-h0arn8u4y9
SCHEMBL21891
KYOBSHFOBAOFBF-XVFCMESISA-N
1,2,3,6-tetrahydro-2,6-dioxo-3-(5-o-phosphono-beta-delta-ribofuranosyl)-4-pyrimidinecarboxylate
5'-(dihydrogen phosphate) orotidine
orotidylate
1,2,3,6-tetrahydro-2,6-dioxo-3-(5-o-phosphono-beta-delta-ribofuranosyl)-4-pyrimidinecarboxylic acid
6-carboxy-5'-uridylate
2,6-dioxo-3-(5-o-phosphono-beta-delta-ribofuranosyl)-1,2,3,6-tetrahydropyrimidine-4-carboxylic acid
5'-phosphate orotidine
1,2,3,6-tetrahydro-2,6-dioxo-3-(5-o-phosphono-b-d-ribofuranosyl)-4-pyrimidinecarboxylic acid
1,2,3,6-tetrahydro-2,6-dioxo-3-(5-o-phosphono-b-d-ribofuranosyl)-4-pyrimidinecarboxylate
5'-(dihydrogen phosphate) 6-carboxy-uridine
AKOS030551158
orotidine 5??-monophosphate
DTXSID40944090
Q27098253
1,2,3,6-tetrahydro-2,6-dioxo-3-(5-o-phosphono-.beta.-d-ribofuranosyl)-4-pyrimidinecarboxylic acid
4-pyrimidinecarboxylic acid, 1,2,3,6-tetrahydro-2,6-dioxo-3-(5-o-phosphono-.beta.-d-ribofuranosyl)-
3-((2r,3r,4s,5r)-3,4-dihydroxy-5-((phosphonooxy)methyl)tetrahydrofuran-2-yl)-2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylic acid
CS-0139119
HY-N8060
orotidine 5 inverted exclamation marka-monophosphate
3-((2r,3r,4s,5r)-3,4-dihydroxy-5-((phosphonooxy)methyl)tetrahydrofuran-2-yl)-2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylicacid
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
pyrimidine ribonucleoside 5'-monophosphate
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (21)

PathwayProteinsCompounds
Pyrimidine Metabolism2353
Glycine and Serine Metabolism2452
beta-Ureidopropionase Deficiency2353
UMP Synthase Deficiency (Orotic Aciduria)2353
Dihydropyrimidinase Deficiency2353
MNGIE (Mitochondrial Neurogastrointestinal Encephalopathy)2353
Dimethylglycine Dehydrogenase Deficiency2452
Dihydropyrimidine Dehydrogenase Deficiency (DHPD)2452
Sarcosinemia2452
Non-Ketotic Hyperglycinemia2452
Hyperglycinemia, Non-Ketotic2452
3-Phosphoglycerate Dehydrogenase Deficiency2452
5'-Orotidylic acid + Pyrophosphate = Orotic acid + D-5-Phospho-ribosyl 1-diphosphate ( Pyrimidine Nucleotides and Nucleosides metabolism )14
Pyrimidine Nucleotides and Nucleosides metabolism ( Pyrimidine Nucleotides and Nucleosides metabolism )4549
Metabolic Epileptic Disorders2589
uridine-5'-phosphate biosynthesis018
pyrimidine ribonucleotides de novo biosynthesis022
superpathway of histidine, purine, and pyrimidine biosynthesis064
De novo biosynthesis of pyrimidine ribonucleotides09
Biochemical pathways: part I0466
Pyrimidine metabolism038
De novo synthesis of UMP221

Protein Targets (4)

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Orotidine 5'-phosphate decarboxylaseMethanothermobacter thermautotrophicus str. Delta HKm3.50002.00003.50005.0000AID268969; AID268970
Orotidine 5'-phosphate decarboxylaseSaccharomyces cerevisiae S288CKm0.70000.70000.70000.7000AID268971
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID268972Affinity for Plasmodium falciparum ODCase at 25 degreeC by UV-based assay2006Journal of medicinal chemistry, Aug-10, Volume: 49, Issue:16
Design of inhibitors of orotidine monophosphate decarboxylase using bioisosteric replacement and determination of inhibition kinetics.
AID268971Affinity for Saccharomyces cerevisiae ODCase at 25 degreeC by UV-based assay2006Journal of medicinal chemistry, Aug-10, Volume: 49, Issue:16
Design of inhibitors of orotidine monophosphate decarboxylase using bioisosteric replacement and determination of inhibition kinetics.
AID268970Affinity for Methanobacterium thermoautotrophicum ODCase at 25 degreeC by ITC method2006Journal of medicinal chemistry, Aug-10, Volume: 49, Issue:16
Design of inhibitors of orotidine monophosphate decarboxylase using bioisosteric replacement and determination of inhibition kinetics.
AID268969Affinity for Methanobacterium thermoautotrophicum ODCase at 55 degreeC by ITC method2006Journal of medicinal chemistry, Aug-10, Volume: 49, Issue:16
Design of inhibitors of orotidine monophosphate decarboxylase using bioisosteric replacement and determination of inhibition kinetics.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (54)

TimeframeStudies, This Drug (%)All Drugs %
pre-199011 (20.37)18.7374
1990's5 (9.26)18.2507
2000's27 (50.00)29.6817
2010's10 (18.52)24.3611
2020's1 (1.85)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 18.22

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index18.22 (24.57)
Research Supply Index4.01 (2.92)
Research Growth Index4.59 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (18.22)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (3.70%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other52 (96.30%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]